436 related articles for article (PubMed ID: 35691607)
1. Antivirals and the Potential Benefits of Orally Inhaled Drug Administration in COVID-19 Treatment.
Sahin G; Akbal-Dagistan O; Culha M; Erturk A; Basarir NS; Sancar S; Yildiz-Pekoz A
J Pharm Sci; 2022 Oct; 111(10):2652-2661. PubMed ID: 35691607
[TBL] [Abstract][Full Text] [Related]
2. Insights into antiviral mechanisms of remdesivir, lopinavir/ritonavir and chloroquine/hydroxychloroquine affecting the new SARS-CoV-2.
Uzunova K; Filipova E; Pavlova V; Vekov T
Biomed Pharmacother; 2020 Nov; 131():110668. PubMed ID: 32861965
[TBL] [Abstract][Full Text] [Related]
3. SARS-CoV-2: Recent Reports on Antiviral Therapies Based on Lopinavir/Ritonavir, Darunavir/Umifenovir, Hydroxychloroquine, Remdesivir, Favipiravir and other Drugs for the Treatment of the New Coronavirus.
Costanzo M; De Giglio MAR; Roviello GN
Curr Med Chem; 2020; 27(27):4536-4541. PubMed ID: 32297571
[TBL] [Abstract][Full Text] [Related]
4. Safety and efficacy of antiviral combination therapy in symptomatic patients of Covid-19 infection - a randomised controlled trial (SEV-COVID Trial): A structured summary of a study protocol for a randomized controlled trial.
Panda PK; Bandyopadhyay A; Singh BC; Moirangthem B; Chikara G; Saha S; Bahurupi YA
Trials; 2020 Oct; 21(1):866. PubMed ID: 33081849
[TBL] [Abstract][Full Text] [Related]
5. Early antiviral treatment in outpatients with COVID-19 (FLARE): a structured summary of a study protocol for a randomised controlled trial.
Brown LK; Freemantle N; Breuer J; Dehbi HM; Chowdhury K; Jones G; Ikeji F; Ndoutoumou A; Santhirakumar K; Longley N; Checkley AM; Standing JF; Lowe DM
Trials; 2021 Mar; 22(1):193. PubMed ID: 33685502
[TBL] [Abstract][Full Text] [Related]
6. Safety profile of COVID-19 drugs in a real clinical setting.
Chiu MN; Bhardwaj M; Sah SP
Eur J Clin Pharmacol; 2022 May; 78(5):733-753. PubMed ID: 35088108
[TBL] [Abstract][Full Text] [Related]
7. Impact of repurposed drugs on the symptomatic COVID-19 patients.
Hussain I; Hussain A; Alajmi MF; Rehman MT; Amir S
J Infect Public Health; 2021 Jan; 14(1):24-38. PubMed ID: 33341481
[TBL] [Abstract][Full Text] [Related]
8. Simultaneous quantification of seven repurposed COVID-19 drugs remdesivir (plus metabolite GS-441524), chloroquine, hydroxychloroquine, lopinavir, ritonavir, favipiravir and azithromycin by a two-dimensional isotope dilution LC-MS/MS method in human serum.
Habler K; Brügel M; Teupser D; Liebchen U; Scharf C; Schönermarck U; Vogeser M; Paal M
J Pharm Biomed Anal; 2021 Mar; 196():113935. PubMed ID: 33548872
[TBL] [Abstract][Full Text] [Related]
9. Molnupiravir in COVID-19: A Scoping Review.
Kaore S; Atal S
Curr Drug Res Rev; 2022; 14(3):203-214. PubMed ID: 35638286
[TBL] [Abstract][Full Text] [Related]
10. An overview of antiviral strategies for coronavirus 2 (SARS-CoV-2) infection with special reference to antimalarial drugs chloroquine and hydroxychloroquine.
Dragojevic Simic V; Miljkovic M; Stamenkovic D; Vekic B; Ratkovic N; Simic R; Rancic N
Int J Clin Pract; 2021 Mar; 75(3):e13825. PubMed ID: 33156564
[TBL] [Abstract][Full Text] [Related]
11. Tissue distributions of antiviral drugs affect their capabilities of reducing viral loads in COVID-19 treatment.
Wang Y; Chen L
Eur J Pharmacol; 2020 Dec; 889():173634. PubMed ID: 33031797
[TBL] [Abstract][Full Text] [Related]
12. COVID-19: Potential Repurposing Drugs.
Leowattana W
Infect Disord Drug Targets; 2022; 22(1):e110122191924. PubMed ID: 33645490
[TBL] [Abstract][Full Text] [Related]
13. An overview of the safety, clinical application and antiviral research of the COVID-19 therapeutics.
Wang D; Li Z; Liu Y
J Infect Public Health; 2020 Oct; 13(10):1405-1414. PubMed ID: 32684351
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of antiviral treatment for COVID-19 from evidence in studies of SARS-CoV-2 and other acute viral infections: a systematic review and meta-analysis.
Liu W; Zhou P; Chen K; Ye Z; Liu F; Li X; He N; Wu Z; Zhang Q; Gong X; Tang Q; Du X; Ying Y; Xu X; Zhang Y; Liu J; Li Y; Shen N; Couban RJ; Ibrahim QI; Guyatt G; Zhai S
CMAJ; 2020 Jul; 192(27):E734-E744. PubMed ID: 32493740
[TBL] [Abstract][Full Text] [Related]
15. A Review of the Preclinical and Clinical Efficacy of Remdesivir, Hydroxychloroquine, and Lopinavir-Ritonavir Treatments against COVID-19.
Maciorowski D; Idrissi SZE; Gupta Y; Medernach BJ; Burns MB; Becker DP; Durvasula R; Kempaiah P
SLAS Discov; 2020 Dec; 25(10):1108-1122. PubMed ID: 32942923
[TBL] [Abstract][Full Text] [Related]
16. Favipiravir, lopinavir-ritonavir, or combination therapy (FLARE): A randomised, double-blind, 2 × 2 factorial placebo-controlled trial of early antiviral therapy in COVID-19.
Lowe DM; Brown LK; Chowdhury K; Davey S; Yee P; Ikeji F; Ndoutoumou A; Shah D; Lennon A; Rai A; Agyeman AA; Checkley A; Longley N; Dehbi HM; Freemantle N; Breuer J; Standing JF;
PLoS Med; 2022 Oct; 19(10):e1004120. PubMed ID: 36260627
[TBL] [Abstract][Full Text] [Related]
17. FDA approved drugs with pharmacotherapeutic potential for SARS-CoV-2 (COVID-19) therapy.
Drożdżal S; Rosik J; Lechowicz K; Machaj F; Kotfis K; Ghavami S; Łos MJ
Drug Resist Updat; 2020 Dec; 53():100719. PubMed ID: 32717568
[TBL] [Abstract][Full Text] [Related]
18. Understanding the binding mechanism for potential inhibition of SARS-CoV-2 Mpro and exploring the modes of ACE2 inhibition by hydroxychloroquine.
Choudhury M; Dhanabalan AK; Goswami N
J Cell Biochem; 2022 Feb; 123(2):347-358. PubMed ID: 34741481
[TBL] [Abstract][Full Text] [Related]
19. Molnupiravir and Nirmatrelvir/Ritonavir: The New Available Antiviral Options for COVID-19.
Sutanto ST; Sinto R; Pasaribu A; Shakinah S
Acta Med Indones; 2022 Oct; 54(4):638-644. PubMed ID: 36624705
[TBL] [Abstract][Full Text] [Related]
20. A comprehensive update on the structure and synthesis of potential drug targets for combating the coronavirus pandemic caused by SARS-CoV-2.
Malik P; Jain S; Jain P; Kumawat J; Dwivedi J; Kishore D
Arch Pharm (Weinheim); 2022 May; 355(5):e2100382. PubMed ID: 35040187
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
